Application of fused immune protein to preparation of medicine for treating multiple sclerosis

A multiple sclerosis and immunoglobulin technology, applied in the field of bioengineering, can solve problems such as toxic side effects, large differences in patient tolerance, and rebound

Inactive Publication Date: 2015-09-23
WUHAN AOSIMEIDE BIOLOGICAL PHARMA CO LTD
View PDF8 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, methylprednisolone has extensive and serious side effects, and the tolerance of patients varies greatly, making it difficult ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of fused immune protein to preparation of medicine for treating multiple sclerosis
  • Application of fused immune protein to preparation of medicine for treating multiple sclerosis
  • Application of fused immune protein to preparation of medicine for treating multiple sclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Example 1: The incidence of experimental mice and the average clinical score at different stages

[0050] When the experiment was terminated on the 42nd day, all the mice in group A had no disease; except for the 24 mice that were sacrificed before the onset of the C57BL / 6J model mice in group C, 41 / 48 (85.4%) of the mice developed the disease. Group C developed symptoms successively 15-20 days after inoculation, peaked at 24-28 days, and maintained for 5-7 days. Some clinical symptoms of the natural course group could be alleviated, and the clinical scores were relatively lower, but the symptoms persisted, and then entered chronic maintenance. In the second stage, the disease showed a typical chronic non-remission process; 29 / 36 (80.5%) mice in group D had the disease, and 28 / 36 (77.8%) mice in group E had the disease; the symptoms were the same as those in the EAE group. One mouse in group E died without disease, which may be related to improper operation during injec...

Embodiment 2

[0055] Example 2: Histopathological and immunohistochemical changes in experimental mouse brain

[0056] After treatment, mouse brain HE and LFB staining can be seen under light microscope (see figure 2 and image 3 ). The infiltration of inflammatory cells was better than that in the peak period and chronic maintenance period of the EAE group, and the demyelination was also alleviated. Abnormal staining due to local aggregation of APP due to axonal damage was not seen. The degree of activation of microglial cells in the brain was significantly reduced in the two treatment groups, and almost returned to normal after treatment with methylprednisolone; it shows that methylprednisolone and fusion protein have anti-inflammatory and anti-myelin damage effects, especially the effect of methylprednisolone more obvious.

[0057] figure 2 A in A is the HE staining of the brains of the mice in the control group; B is the HE staining of the brains of the mice in the EAE group in t...

Embodiment 3

[0065] Example 3: Changes in the permeability of the blood-brain barrier

[0066] Such as Figure 9 As shown in Table 2, the EAE group has always maintained a high level at the peak of the onset and the chronic maintenance period, and no significant changes have been observed after fusion immunoglobulin treatment, and there is no statistical difference compared with the peak of the onset and the chronic maintenance period (P>0.05 ), the permeability of the blood-brain barrier in the methylprednisolone group decreased, which was statistically different from that in the EAE group (P<0.05; indicating that methylprednisolone can inhibit the increase in the permeability of the blood-brain barrier, while fusion immune Globulin did not show this effect.

[0067] Table 2 Changes of EB content (μg / g brain tissue) in hippocampal tissue of experimental mice

[0068]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of a fused immune protein to preparation of medicine for treating multiple sclerosis and belongs to the field of biological engineering. The fused immune protein has specific effect of relieving chronic EVE (experimental autoimmune encephalomyelitis) mouse clinical impairment. In a treatment course, hormone-like drug withdrawal rebound phenomenon does not appear. The fused immune protein can be used for preparing the medicine for treating multiple sclerosis independently or can be used for preparing the medicine for treating multiple sclerosis with other medicines.

Description

technical field [0001] The invention relates to the application of fusion immunoglobulin in the preparation of medicines for treating multiple sclerosis, belonging to the field of bioengineering. Background technique [0002] Multiple sclerosis (MS) is a type of complex and diverse clinical manifestations and pathological changes, with varying course and prognosis. During the course of the disease, there are often symptoms of remission and relapse of nervous system damage. MS is an inflammatory autoimmune disease with scattered white matter / multifocal demyelination of the central nervous system as the main pathological changes, which may be accompanied by varying degrees of axonal damage. Demyelinating lesions are common around white matter venules and lateral ventricles, accompanied by infiltration of lymphocytes and monocyte-macrophages. Immunofluorescence examination shows intrathecal deposition of IgG, suggesting immune activation. The pattern of demyelination or oligod...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/395A61P37/02A61P25/00
Inventor 张蕲周翔鱼祝道成周雄
Owner WUHAN AOSIMEIDE BIOLOGICAL PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap